Why Is Hims & Hers Health (HIMS) Stock Up +4.22% Today?
Key Takeaways
- HIMS shares climbed 4.22% to approximately $30.59, building on a strong prior session.
- The advance followed a 4.86% gain in the previous completed session, signaling renewed momentum rather than a single company-specific headline.
- Bullish options activity stood out, with call volume far outpacing puts and a put/call ratio well below its typical level.
- Optimism around the company's branded weight-loss expansion, anchored by its Novo Nordisk distribution partnership, continued to support sentiment.
- Trading volume was lighter than average, a caveat that suggests conviction may be narrower than the price move implies.
Opening Summary
Hims & Hers Health, Inc. (HIMS), a direct-to-consumer telehealth platform offering treatments across weight loss, sexual health, hair loss, and mental health, rose 4.22% on Tuesday. The stock advanced to roughly $30.59 from a prior closing price of $29.35, extending the gains that began in the previous session. The move reflected continued investor enthusiasm for the company's shift toward branded GLP-1 weight-loss therapies and its expanding subscriber base, even as the session lacked a single dominant news catalyst.
Momentum and a Broader Growth Narrative
The rally did not hinge on one isolated announcement. Instead, investors appeared to be rewarding the company's improving growth trajectory. Hims & Hers reported second-quarter revenue of $753.2 million, up 38.2% year over year, and raised its full-year 2026 revenue outlook to a range of $3.1 billion to $3.3 billion. Subscribers climbed to roughly 2.9 million, while monthly revenue per average subscriber rose 21.1% to $92, evidence that the platform is both adding customers and monetizing each one more effectively.
A central pillar of the bull case is the company's strategic pivot toward branded GLP-1 medications. Under its distribution agreement with Novo Nordisk, Hims & Hers gives customers access to treatments such as Wegovy and Ozempic. The partnership is widely viewed as reducing regulatory and legal uncertainty that had long weighed on the company's compounded weight-loss business, while positioning the platform to capture durable demand in the fast-growing obesity-treatment market.
Options Flow and Technical Tailwinds
Market reaction during the session pointed to bullish positioning among traders. Options volume ran well above average, with calls leading puts and a put/call ratio of roughly 0.18 compared with a more typical level near 0.44. That skew indicated that a meaningful portion of the day's activity reflected bets on further upside rather than hedging against a decline. Implied volatility ticked higher but remained near the lower end of its one-year range, consistent with a modestly bullish tone.
The move also carried technical significance. The stock traded above its 50-day moving average near $29.96 and remained comfortably above its 200-day moving average near $27.78, reinforcing the impression that the medium-term trend has turned higher after a volatile stretch earlier in 2026.
Market Context and Trading Activity
Notably, the advance came on relatively light volume. About 7.2 million shares changed hands through midday, well below the stock's average session volume of roughly 24 million. A price rally on below-average participation can suggest that the move was driven by momentum-oriented and options-related activity rather than broad institutional accumulation, and it leaves the session's gains more susceptible to reversal if sentiment cools.
The move was also consistent with lingering strength across the telehealth and digital-health space, where companies exposed to branded weight-loss treatments have benefited from sustained consumer demand. Hims & Hers outperformed the broader tone, however, reflecting stock-specific catalysts tied to its growth outlook rather than a simple sector rotation. Against this backdrop, analysts maintain a consensus "Hold" rating, with a wide range of views reflecting the tension between rapid revenue expansion and near-term margin pressure.
What Comes Next for HIMS
Investors will be watching several factors in the coming weeks. The company's third-quarter results will be a key test of whether its branded GLP-1 transition can sustain revenue momentum while stabilizing margins that compressed sharply in the second quarter. Gross margin contracted to 63.8% as the company shifted toward lower-margin branded products and invested in international expansion, and the company posted a net loss of $86.3 million in the most recent quarter.
Regulatory and legal developments also remain in focus. A Federal Trade Commission complaint and related securities-fraud class-action solicitations continue to hang over the stock, along with reports of insider stock sales. These issues have not derailed the recent rebound, but they represent recurring sources of headline risk. The durability of the current rally will likely depend on whether the company can demonstrate that branded weight-loss adoption, subscriber growth, and international scale translate into more stable profitability over time.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and the symbols they trade. Only the most consistent performers are featured in this section, giving traders a focused view of which automated strategies are currently adapting best to the market. Explore the Trending AI Robots to see which strategies are leading today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HIMS in +5.24% Uptrend, growing for three consecutive days on September 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in 243 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 61 cases where HIMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on September 18, 2026. You may want to consider a long position or call options on HIMS as a result. In 70 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on September 18, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
HIMS moved below its 50-day moving average on August 24, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
HIMS broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HIMS entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.161) is normal, around the industry mean (43.618). P/E Ratio (57.137) is within average values for comparable stocks, (141.316). Projected Growth (PEG Ratio) (2.552) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement